Skip to main content

Table 2 NCCN recommended single agents and combination regimens

From: Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims

Single agents

Doxorubicin

Ifosfamide

Epirubicin

Gemcitabine

Dacarbazine

Liposomal doxorubicin

Temozolomide

Vinorelbine

Eribulin

Trabectedin

Pazopanib

Regorafenib

Larotrectinib

Combination regimens

AD: doxorubicin, dacarbazine

AIM: doxorubicin, ifosfamide, mesna

MAID: mesna, doxorubicin, ifosfamide, dacarbazine

Ifosfamide, epirubicin, mesna

Gemcitabine and docetaxel

Gemcitabine and vinorelbine

Gemcitabine and dacarbazine

Doxorubicin and olaratumab (October 2016- July 2018 only)